Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)Retained EarningsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InflaRx (IFRX) Common Equity (2022 - 2025)

Historic Common Equity for InflaRx (IFRX) over the last 4 years, with Q3 2025 value amounting to $53.0 million.

  • InflaRx's Common Equity fell 2602.45% to $53.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $53.0 million, marking a year-over-year decrease of 2602.45%. This contributed to the annual value of $66.5 million for FY2024, which is 3977.36% down from last year.
  • As of Q3 2025, InflaRx's Common Equity stood at $53.0 million, which was down 2602.45% from $64.6 million recorded in Q2 2025.
  • In the past 5 years, InflaRx's Common Equity ranged from a high of $135.7 million in Q2 2023 and a low of $53.0 million during Q3 2025
  • Its 4-year average for Common Equity is $92.4 million, with a median of $90.1 million in 2022.
  • Its Common Equity has fluctuated over the past 5 years, first surged by 2810.69% in 2023, then tumbled by 4418.19% in 2024.
  • Quarter analysis of 4 years shows InflaRx's Common Equity stood at $90.1 million in 2022, then grew by 22.45% to $110.4 million in 2023, then plummeted by 40.54% to $65.6 million in 2024, then fell by 19.19% to $53.0 million in 2025.
  • Its Common Equity stands at $53.0 million for Q3 2025, versus $64.6 million for Q2 2025 and $74.1 million for Q1 2025.